cyclo therapeutics inc shares rose 21 to 209 as it provided a business update and several companies working on treatments for alzheimers disease had higher stock prices biogen inc and eisai co said tuesday that their experimental alzheimers drug significantly slowed progression of the disease in a study cyclo said it is very pleased with our progress advancing our clinical programs evaluating trappsol cyclo for the treatment of niemannpick disease type c and alzheimers the company said it is on track to begin enrollment and dosing of a phase 2 study for alzheimers before yearend